Eversheds Sutherland advises Azurity Pharmaceuticals on Acquisition of Sebela’s Bowel Prep Franchise
November 24, 2025
Eversheds Sutherland is pleased to have advised Azurity Pharmaceuticals on its acquisition of Sebela’s Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies.
The strategic transaction further strengthens Azurity’s commitment to serving overlooked patients by advancing access to medicines. By integrating Sebela’s bowel prep franchise, Azurity will expand its product offerings and capabilities to healthcare providers and patients in the United States.
With the acquisition, Azurity welcomes more than 50 colleagues from Sebela’s commercial and support teams.
Read Azurity’s press release here.
The Eversheds Sutherland team was led by Partner Mike Voynich (Corporate), with support from Partner Pete Pappas (Intellectual Property), Special Counsel Anna Halsey (Intellectual Property), Senior Associate Adam Byrne (Corporate) and Associate Haley Klass (Corporate).
Key contacts
Latest News
- firm newsEversheds Sutherland advises OCBC on the landmark secondary dual listing of PT Merdeka Gold Resources Tbk on the Hong Kong Stock Exchange
- client newsSetting sail: Eversheds Sutherland advises senior management of D-Marin on acquisition by InfraVia
- client newsEversheds Sutherland advises Costello Medical on transition to employee ownership
- firm newsEversheds Sutherland lands lateral partner-led Paris Funds team, as its wider European private capital push continues
Latest Events
firm news
July 10, 2026
Eversheds Sutherland advises OCBC on the landmark secondary dual listing of...
client news
July 10, 2026
Setting sail: Eversheds Sutherland advises senior management of D-Marin on ...
client news
July 09, 2026
Eversheds Sutherland advises Costello Medical on transition to employee own...
firm news
July 01, 2026
Eversheds Sutherland lands lateral partner-led Paris Funds team, as its wid...